CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 30 enrolled
Drug / intervention
E coli strain H10407 and buffer +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00844493
NCT00844493Phase 1Completed

Validation of Low-dose ETEC Challenge Model in U.S. Adults and Re-challenge of Immune Subjects With a Homologous ETEC Strain (H10407)

Johns Hopkins Bloomberg School of Public Health·interventional·Posted Feb 16, 2009·Updated Sep 12, 2014

In Brief

A Phase 1 clinical trial evaluating E coli strain H10407 and buffer and E coli H10407 and buffer for Diarrhea. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This study will validate a model for testing new vaccines designed to protect against intestinal infections with enterotoxigenic Escherichia coli (ETEC). ETEC is one of the most common causes of diarrhea in developing countries and is a common cause of travelers diarrhea. Vaccines are now being developed and their development will be facilitated if we have a valid model for testing these vaccines in human volunteers. We anticipate that the new vaccines will be given to volunteers and they will then be given a dose of virulent ETEC bacteria. If the vaccine is effective, the volunteers should not development diarrhea, but if the vaccine is not effective, the volunteers will have diarrhea for a few days. During this study, we will validate a minimum dose of virulent ETEC bacteria which is sufficient to cause diarrhea in healthy adult volunteers and to identify conditions that can make this model reliable. We will also determine, in a follow-up group of volunteers, if being exposed to the ETEC bacteria previously will protect against a subsequent illness when they are exposed to the same bacteria a second time. We believe that the previously exposed group will be protected and we will study the immune response to these exposures to help design vaccines that can accomplish this kind of protection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiarrhea
CountriesUnited States

Timeline

Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 16, 2009
Enrollment StartFeb 1, 2009
Primary CompletionFeb 1, 2012
Study CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 17.4 years ago

Interventions

E coli strain H10407 and bufferbiological

7 or 8 logs of the bacteria with bicarbonate buffer

E coli strain H10407 and bufferbiological

Bacteria in a dose of 8 logs with CeraVacx buffer

E coli strain H10407 and bufferbiological

Bacteria in a dose of 7 logs and CeraVacx buffer

E coli H10407 and bufferbiological

Bacteria in a dose of 8 logs with bicarbonate buffer